Back to top
more

Atreca (BCEL)

(Delayed Data from OTC)

$0.09 USD

0.09
57,501

0.00 (4.65%)

Updated Jun 7, 2024 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BCEL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Atreca, Inc. [BCEL]

Reports for Purchase

Showing records 121 - 140 ( 159 total )

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 121

06/16/2020

Daily Note

Pages: 11

Preclinical Insights on Proposed ATRC- 101 MOA Highlight Power of the Platform

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 122

06/10/2020

Daily Note

Pages: 5

Window Into the Future? We Certainly Think So; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 123

06/03/2020

Industry Report

Pages: 55

ASCO 2020: Covered Companies Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 124

05/15/2020

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 125

05/15/2020

Company Report

Pages: 6

1Q20 Results; Driving Towards Initial ATRC-101 Data and a COVID-19 Candidate

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 126

05/15/2020

Industry Report

Pages: 19

CORRECTED: ASCO Virtual Meeting Abstract Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 127

05/15/2020

Company Report

Pages: 5

1Q20: Further Progress Throughout 2020

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 128

05/15/2020

Company Report

Pages: 6

Q1 Financials; ATRC-101 Ph 1b Enrollment Progressing

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 129

05/13/2020

Daily Note

Pages: 7

Healthcare-Check Out Our Highlights From 2020 ASCO Abstracts

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 130

04/30/2020

Company Report

Pages: 6

Going Back to Atreca''s Roots; Leveraging IRC Platform for COVID-19

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 131

04/30/2020

Company Report

Pages: 5

A Unique Value Add Collaboration on Novel Antibody Treatment for COVID-19

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 132

04/30/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 133

04/30/2020

Industry Report

Pages: 3

Reminder to Register for Our ASCO Abstract Titles Webinar

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 134

04/29/2020

Industry Report

Pages: 6

Time to Bring the B (Cell) Team into the COVID Wars

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 135

04/22/2020

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 136

04/22/2020

Company Report

Pages: 29

Differentiated Antibody Discovery Addresses Targets off the Beaten Path; Initiating at Buy and $30 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 75.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 137

04/21/2020

Company Report

Pages: 37

We Are Initiating with OUTPERFORM and $27 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 75.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 138

04/21/2020

Company Report

Pages: 37

Initiating with OUTPERFORM and $27 PT; From Bedside to Bench and Back Again

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 75.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 139

03/18/2020

Company Report

Pages: 7

Takeaways From Our KOL Call-Can Antibodies Help Drive Antitumor Responses

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Atreca, Inc.

Industry: Medical - Biomedical and Genetics

Record: 140

03/18/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party